Regulator is exploring safety of immunotherapy combinations in blood cancer
FDA is investigating safety of immunotherapies in blood cancer.
FDA gives green light after 7-year absence
UK biotech will supply key component of Novartis’ newly approved cancer cell therapy
Regulator reviewing combination therapy safety after issue with Keytruda